Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of CHEMO PHARMA LABORATORIES LTD. ₹50.19, price ₹79.00, upside -36.5%, quality 63 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
CP
Thin data
Sep 27, 2026
CHEMO PHARMA LABORATORIES LTD.
CHEMOPH · BSEStretched ValuationStrong overvaluation with only moderate quality.
Quality 63/100
Mixed vs. peers (4/7)
Fair value ₹50.19 · Strongly overvalued (−36.5%)
Negative free cash flow
Narrow moat 24/100
Thin data
Watch CHEMO PHARMA LABORATORIES LTD. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹17.85 – ₹150.65 · fair‑value band ₹37.64 – ₹54.90 · the ₹79.00 price screens above the ₹50.19 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow CHEMO PHARMA LABORATORIES in your weekly email
Every Wednesday you see whether CHEMO PHARMA LABORATORIES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Chemo Pharma Laboratories Limited does not have significant operations. Previously, the company was engaged in the finance and investment activities. Chemo Pharma Laboratories Limited was incorporated in 1942 and is based in Mumbai, India.
Stock analysis
CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) currently trades at ₹79.00, while our model-based Fair Value estimate is ₹50.19, 36.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Economic Profit group reads highest at a median of ₹59.01 per share, and 0 of the 8 models we run sit above the ₹79.00 price.
Bear case: the Earnings-Based group reads lowest at ₹11.41, and 8 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹37.64 (bear) to ₹54.90 (bull), the price of ₹79.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Healthcare sector.
CHEMO PHARMA LABORATORIES LTD. reported revenue of ₹0 in FY2025 versus ₹0 in FY2021. Reported net income was ₹3.4M in FY2025, compounding +8.2%/yr from FY2021.
Key figures
Market cap ₹196M (≈ $2.0M) · P/S ratio 84.1 · EPS (TTM) ₹−81.48 · Return on equity −162% · Return on assets (EBIT) −1.8% · Operating margin 18.7% · Revenue (TTM) ₹2.3M · Revenue growth (YoY) −16.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 46% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −36%, CHEMOPH screens richer than that median.
Fair Value models
Bear ₹37.64
Fair Value ₹50.19
Bull ₹54.90
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
P/E Multiple
₹37.64
₹50.19
₹62.74
63
Residual Income
₹61.86
₹59.01
₹59.00
61
Growth-Adj P/E
₹29.45
₹42.07
₹54.69
59
All 8 models by family
Earnings-Based
Graham-Dodd
₹15.51
₹41.27
₹53.95
51
Lynch FV
₹7.98
₹11.41
₹14.83
48
PEG = 1.0
₹7.98
₹11.41
₹14.83
45
Multiples
P/E Multiple
₹37.64
₹50.19
₹62.74
63
P/B Multiple
₹29.09
₹38.78
₹48.48
55
Asset-Based
NCAV (Graham)
₹43.82
₹58.71
₹87.63
51
Economic Profit
Residual Income
₹61.86
₹59.01
₹59.00
61
Growth Earnings
Growth-Adj P/E
₹29.45
₹42.07
₹54.69
59
Notify me when CHEMOPH reaches fair value
Put CHEMOPH on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
63/100
Of which business quality 67 · Market factors (momentum, volatility) 25
Profitability
14
Margins and returns on capital today
Quality Growth
25
Are margins and returns improving?
Cashflow
100
Earnings quality: real cash, not paper profit
Fin. Strength
100
Balance sheet, leverage, solvency risk
Investment
78
Disciplined investing over empire-building
Low Volatility
50
Calm price path (market factor)
Momentum
20
Price trend over the last 3–12 months (market factor)
52W Momentum
5
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+6.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.5%
Dividend (yield on the price)0.0%
Compare CHEMO PHARMA LABORATORIES LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 602 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹50.19 versus a price of ₹79.00, about −36% upside (overvalued).
What is the fair value of CHEMOPH?
Our model-based fair value for CHEMO PHARMA LABORATORIES LTD. is ₹50.19 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹79.00.
What is the quality score of CHEMOPH?
CHEMO PHARMA LABORATORIES LTD. has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Our model-based price target is the fair value of ₹50.19 (as of Sep 27, 2026) from 8 valuation models. Cautious scenario ₹37.64, optimistic scenario ₹54.90. It is a calculation from audited fundamentals, not an analyst target.
What is the CHEMO PHARMA LABORATORIES LTD. stock forecast for 2026?
Our models put fair value at ₹50.19, about −36% upside versus a price of ₹79.00 (overvalued). Cautious scenario ₹37.64, optimistic scenario ₹54.90. The calculation is refreshed regularly with new filings.
What is the revenue of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
CHEMO PHARMA LABORATORIES LTD. reported trailing-twelve-month revenue of about ₹2.3M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHEMO PHARMA LABORATORIES LTD. it is ₹50.19 per share (as of Sep 27, 2026), against a price of ₹79.00. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is CHEMO PHARMA LABORATORIES LTD. stock overvalued or undervalued in 2026?
As of Sep 27, 2026, CHEMOPH trades above its calculated fair value: price ₹79.00, fair value ₹50.19, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CHEMOPH?
No. The price is what the market pays today (₹79.00); the fair value is what the company's own numbers justify (₹50.19). For CHEMO PHARMA LABORATORIES LTD. the two are ₹28.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is CHEMO PHARMA LABORATORIES LTD. worth?
The market values CHEMO PHARMA LABORATORIES LTD. at about ₹196M (market capitalisation, as of Sep 27, 2026). Per share that is ₹79.00; our models calculate a fair value of ₹50.19 per share.
What do the bullish and bearish scenarios say about CHEMOPH?
Our models span a range for CHEMO PHARMA LABORATORIES LTD.: cautious scenario ₹37.64, base ₹50.19, optimistic ₹54.90 per share (as of Sep 27, 2026, price ₹79.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Balance-sheet figures for CHEMO PHARMA LABORATORIES LTD. (as of Sep 27, 2026): return on equity −161.9%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is CHEMOPH from its 52-week high?
CHEMO PHARMA LABORATORIES LTD. trades at ₹79.00, about 46% below its 52-week high of ₹145.75 and 11% above the low of ₹71.01 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹50.19 is for.
Which stocks are comparable to CHEMO PHARMA LABORATORIES LTD.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHEMO PHARMA LABORATORIES LTD. stock attractive at the current price?
The data as of Sep 27, 2026: price ₹79.00, calculated fair value ₹50.19 (−36%), Quality Score 63/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CHEMOPH calculated?
We run CHEMO PHARMA LABORATORIES LTD. through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹50.19, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. CHEMO PHARMA LABORATORIES LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The closing price on Oct 1, 2026 was ₹79.00. Our model-based fair value is ₹50.19, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHEMO PHARMA LABORATORIES LTD. right now?
The price sits above even our optimistic bull case (₹54.90). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of CHEMO PHARMA LABORATORIES LTD.
How large is the market capitalisation of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The market capitalisation of CHEMO PHARMA LABORATORIES LTD. is ₹196M (≈ $2.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The price-to-sales ratio of CHEMO PHARMA LABORATORIES LTD. is 84.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Earnings per share at CHEMO PHARMA LABORATORIES LTD. are ₹−81.48. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The return on equity (ROE) of CHEMO PHARMA LABORATORIES LTD. is −162% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
On an EBIT basis the return on assets of CHEMO PHARMA LABORATORIES LTD. is −1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
The operating margin of CHEMO PHARMA LABORATORIES LTD. is 18.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Revenue at CHEMO PHARMA LABORATORIES LTD. is growing −16.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at CHEMO PHARMA LABORATORIES LTD. (CHEMOPH)?
Earnings per share at CHEMO PHARMA LABORATORIES LTD. are growing −84.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does CHEMO PHARMA LABORATORIES LTD. (CHEMOPH) generate?
The free cash flow of CHEMO PHARMA LABORATORIES LTD. is −₹2.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch CHEMO PHARMA LABORATORIES LTD. in the live analysis
One click puts CHEMO PHARMA LABORATORIES LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.